People: Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

19 Sep 2019
Change (% chg)

€1.25 (+0.87%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rowe, Howard 

Dr. Howard Rowe, J.D. has been Non-Executive Independent Director of Galapagos NV since August 5, 2010. He is also Member of the Audit Committee. He was previously Managing Director with Goldman Sachs where he had multiple Healthcare responsibilities over his 12 years at the firm. His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. During that time he served on the boards of EUSA Pharma, Healthcare Brands International, MedAvante, SmallBone Innovations and Ikonisys. Prior to his investing activities, Dr. Rowe was Senior Member of the European Healthcare Investment Banking team, where he advised numerous corporate clients on Mergers & Acquisitions and corporate finance activities. Before joining Goldman Sachs, he was Corporate Lawyer with the law firm Sullivan & Cromwell. In the past, Mr. Rowe has served as a member of the board of directors of MedAvante, Inc. He is Member of the Board of Managers of Paradigm Spine LLC. Dr. Rowe received his Bachelor of Science in Psychobiology from the University of Southern California, and his Juris Doctor from Harvard Law School.

Basic Compensation

Total Annual Compensation, EUR 45,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 45,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --